KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Exploratory biomarker analysis from a phase III study of the PI3K inhibitor, copanlisib, in combination with rituximab in patients with indolent non-Hodgkin lymphoma, a retrospective study.

Shalini Chaturvedi, Anke Weispfenning, Tine Descamps, Sara Bellinvia, David Bauer, Rong Du, Teresa Lunt, Lidia Mongay Soler, Barrett H Childs, Pier Luigi Zinzani

Clin Transl Oncol 27(8) 3439-3448

PMID39984775
PMCIDPMC12259725
DOI10.1007/s12094-025-03869-2
发表日期2025-02-21
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图。
摘要

摘要

PURPOSE: There has been increased difficulty in developing safe and effective treatment using PI3K inhibitors in heme malignancies, despite the role of PI3K/AKT being well defined in this population. This study was an attempt to conduct exploratory biomarker analysis retrospectively from the phase III CHRONOS-3 trial with the aim to identify a sub-set of patients that could benefit from treatment. PATIENTS AND METHODS: Patients with CD20-positive indolent B-cell lymphoma were randomized 2:1 to receive intravenous copanlisib plus rituximab (C + R) or placebo plus rituximab (P + R). Biomarker analyses were performed to examine potential associations between treatment outcome and phosphatase and tensin homolog (PTEN) protein expression, EZH2 and BCL2 mutation status via next-generation sequencing, and plasma cytokine levels. RESULTS: PTEN presence was associated with significant improvements in progression-free survival (PFS) for C + R over P + R in patients with iNHL (P = 0.001) and FL (P = 0.012). Both the mutant and wild-type EZH2 FL patients had equal PFS benefits when treated with copanlisib. A significant improvement in PFS was observed for patients with mutant versus wild-type BCL2 FL in the C + R arm (P = 0.002). Overall survival (OS) was significantly improved for patients with iNHL and low or undetectable versus high baseline IL-2 levels in the C + R arm (P < 0.0001, unadjusted). CONCLUSIONS: PTEN presence, BCL2 mutations, and low or undetectable baseline IL-2 levels were associated with improved patient survival following treatment with C + R, supporting a potential role for these biomarkers in guiding treatment selection for patients with indolent non-Hodgkin lymphoma.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Patient disposition and biomarker eligibility. a Eligible patients had a diagnosis of CD20-positive indolent B-cell lymphoma (FL grades 1–3a, marginal zone lymphoma, small lymphoplasmacytic lymphoma, or lymphoplasmacytic lymphoma/Waldenström macroglobulinemia), had relapsed following a regimen containing rituximab, a rituximab biosimilar, or an anti-CD20 monoclonal antibody, and were progression- and treatment-free for 12 months since the last rituximab-containing regimen, or for 6 months and unwilling or unfit to receive chemotherapy. b The non-FL cohort included marginal zone lymphoma, small lymphoplasmacytic lymphoma, and lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. IHC immunohistochemistry, NGS next-generation sequencing, PD progressive disease
非 KM Figure
Fig. 2PFS by PTEN status in patients with iNHL. C copanlisib, P placebo, R rituximab
非 KM Figure
Fig. 3PFS by PTEN status in patients with FL. C copanlisib, NA not available, P placebo, R rituximab
非 KM Figure
Fig. 4Association of A BCL2 mutation status and B EZH2 mutation status with PFS response by treatment in patients with FL. C copanlisib, NA not available, P placebo, R rituximab
非 KM Figure
Fig. 5OS by baseline levels of IL-2 in A patients with iNHL and B patients with FL. C copanlisib, NA not available, P placebo, R rituximab
非 KM Figure